View metadata, citation and similar papers at core.ac.uk
brought to you by CORE
provided by Digital.CSIC

2011-01-00217A-Z

Targeted gene correction of α_1-antitrypsin deficiency in induced pluripotent stem cells

Kosuke Yusa[1*], S. Tamir Rashid[2,3*], Helene Strick-Marchand[4], Ignacio Varela[5], Pei-Qi Liu[6], David E. Paschon[6], Elena Miranda[3,7], Adriana Ordóñez[3], Nick Hannan[2], Foad Rouhani[1], Sylvie Darche [4], Graeme Alexander[3], Stefan J. Marciniak[3], Noemi Fusaki [8], Michael C. Holmes[6], James P. Di Santo[4], David A. Lomas[3 §], Allan Bradley[1 §] and Ludovic Vallier[2 §]

*/§ These authors contributed equally to this work

Correspondence should be addressed to:

Allan Bradley (abradley@sanger.ac.uk)

Ludovic Vallier (lv225@cam.ac.uk)

[1] Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, CB10 1SA, UK

[2] Laboratory for Regenerative Medicine, Department of Surgery, West Forvie Building, Robinson Way, University of Cambridge, Cambridge, CB2 0SZ, UK

[3] Department of Medicine, University of Cambridge, Cambridge Institute for Medical Research, Wellcome Trust/MRC Building, Hills Road, Cambridge. CB0 2XY, UK

[4] Innate Immunity Unit, Institut Pasteur, Institut National de la Sante´ et de la Recherche Medicale U668 , Paris, France

[5] Instituto de Biomedicina y Biotecnología de Cantabria (IBBTEC), CSIC-UC-SODERCAN Avda. Cardenal Herrera Oria s/n 39011 Santander, Spain

[6] Sangamo BioSciences Inc., Richmond, CA 94804, USA

[7] Dept. Biologia e Biotecnologie 'Charles Darwin', Universita' "La Sapienza", Rome, Italy

[8] DNAVEC Corporation, Ibaraki 1-25-11, Japan

Main text

Human induced pluripotent stem cells (hIPSCs) represent a unique opportunity for regenerative medicine since they offer the prospect of generating unlimited quantities of cells for autologous transplantation as a novel treatment for a broad range of disorders[1,2,3,4]. However, the use of hIPSCs in the context of genetically inherited human disease will require correction of disease-causing mutations in a manner that is fully compatible with clinical applications[3,5]. The methods currently available, such as homologous recombination, lack the necessary efficiency and also leave residual sequences in the targeted genome[6]. Therefore, the development of new approaches to edit the mammalian genome is a prerequisite to delivering the clinical promise of hIPSCs. Here, we show that a combination of zinc finger nucleases (ZFNs)[7] and *piggyBac*[8,9] technology in hIPSCs can achieve bi-allelic correction of a point mutation (Glu342Lys) in the *α_1-antitrypsin* (*A1AT*, also called *SERPINA1)* gene that is responsible for α_1-antitrypsin deficiency (A1ATD). Genetic correction of hIPSCs restored the structure and function of A1AT in subsequently derived liver cells *in vitro* and *in vivo*. This approach is significantly more efficient than any other gene targeting technology that is currently available and crucially prevents contamination of the host genome with residual non-human sequences. Our results provide the first proof of principle for the potential of combining hIPSCs with genetic correction to generate clinically relevant cells for autologous cell-based therapies.

Currently available methods for gene targeting rely on positive selection to isolate rare clones that have undergone homologous recombination. To remove the unwanted selection cassettes, Cre/*loxP* or Flp/*FRT* recombination systems are used, which leave behind single *loxP* or *FRT* sites[10,11]. These small ectopic sequences have the potential to interfere with transcriptional regulatory elements of surrounding genes, most of which are not fully characterized in the human genome. An alternative method to remove

selection cassettes is to convert them into transposons. The most suitable transposon for this purpose is *piggyBac*, a moth-derived DNA transposon, which can transpose efficiently in mammalian cells including human embryonic stem cells (hESCs)[9,12]. A remarkable feature of this mobile element is seamless excision, which enables removal of transgenes flanked by *piggyBac* inverted repeats without leaving any residual sequences[9,13].

To explore the use of *piggyBac* for the correction of point mutations, we designed a vector to correct a missense mutation (G290T) in the *Tyr* gene in mouse induced pluripotent stem cells (mIPSCs) isolated from fibroblasts of the C57Bl6-*Tyr*$^{c\text{-}Brd}$ strain[14]. This genetic defect results in an albino phenotype that can be monitored through observation of the coat color. A targeting vector was constructed, carrying a wild-type 290G sequence and a *PGK-puΔtk* cassette flanked by *piggyBac* inverted repeats into the TTAA site, 269 bp downstream of the mutation (Fig. 1a). Targeted clones were identified and verified by Southern blot and PCR analyses (Fig. 1b, c). All targeted clones showed correction of the point mutation. The selection cassette was then excised from the mIPSCs genome by transient expression of the *piggyBac* transposase followed by FIAU selection. Transposon excision was verified by Southern blot and PCR analyses (Fig. 1b, c). The correction of the G290T mutation and seamless *piggyBac* excision were confirmed by sequence analyses (Fig. 1d, e). Two introduced silent mutations observed following targeting and excision confirmed that the T290G substitution was mediated by gene correction, not by spontaneous reversion (Fig. 1e). The function of the reverted allele was tested by injecting the corrected mIPSCs into albino mouse blastocysts. The resulting chimeric mice displayed a black coat color, indicating phenotypic correction of the albino mutation (Fig. 1f). These results collectively demonstrate that the *piggyBac* transposon can be used as a versatile tool for highly precise modification (e.g. correction or mutation) of the mammalian genome at a single base-pair level.

We next explored whether this approach could be used to correct a mutation in hIPSCs derived from individuals with α_1-antitrypsin deficiency (A1ATD)[15]. A1ATD is an autosomal recessive disorder found in 1 out of 2000 individuals of North European

descent and represents the most common inherited metabolic disease of the liver[16,17]. It results from a single point mutation in the *A1AT* gene (the *Z* allele; Glu342Lys) that causes the protein to form ordered polymers within the endoplasmic reticulum of hepatocytes[16,17]. The resulting inclusions cause cirrhosis for which the only current therapy is liver transplantation. The increasing shortage of donors and harmful effects of immunosuppressive treatments impose major limitations on organ transplantation, making the potential of hIPSC-based therapy highly attractive. Since homologous recombination is relatively inefficient in human pluripotent stem cells[6], we employed ZFN technology, which stimulates gene targeting in hESCs as well as hIPSCs[7,10,18]. ZFN pairs were designed to specifically cleave the site of the *Z* mutation (Fig. 2a-c, Supplementary Table 1 and Supplementary Note). A targeting vector was constructed from isogenic DNA with *piggyBac* repeats flanking the *PGK-puΔtk* cassette (Fig. 2a). To minimize the distance between the mutation and the *piggyBac* transposon, a CTG leucine codon, 10 bp upstream of the mutation, was altered to a TTA leucine codon, generating the TTAA sequence, which would be left in the genome following *piggyBac* excision (Fig. 2b).

Puromycin-resistant hIPSC colonies obtained after co-electroporation of ZFN expression vectors and the targeting vector were screened for targeted clones by PCR. A1ATD-hIPSC lines derived from 3 different patients yielded targeted clones (Table 1a). Remarkably, 54% of the puromycin-resistant colonies were targeted on one allele, while 4% were the result of simultaneous targeting of both alleles (Supplementary Fig. 1).

To remove the *piggyBac*-flanked selection cassette from these modified clones, we transiently transfected 2 homozygously targeted clones (B-16 and C-G4) with a hyperactive form of the *piggyBac* transposase[8] and subjected them to FIAU selection. The genotype of the resulting FIAU-resistant colonies was analyzed by PCR and confirmed by Southern blot (Fig. 2d and Supplementary Fig. 2a). Bi-allelic excision was observed in 11% of FIAU-resistant colonies (Table 1b). Sequence analyses further demonstrated that the *Z* mutation was corrected on both alleles and that transposon excision yielded a TTAA sequence as initially planned (Fig. 2b, e and Supplementary Fig. 2b). To ensure that the genome modifications had not altered the pluripotency of the

corrected A1ATD-hIPSCs (c-hIPSCs), we confirmed that the resulting c-hIPSC lines maintained the expression of pluripotency markers (OCT4, SOX2, NANOG and TRA1-60) for more than 20 passages and their abilities to differentiate into cells expressing markers of the three germ layers (Supplementary Fig. 3).

Genomic instability is known to be associated with prolonged culture of hESCs[19,20] and those arising during genome modification would be another concern for clinical application of hIPSCs. Therefore, we analyzed the genomic integrity of the hIPSCs lines using array-based comparative genomic hybridization (CGH) (Supplementary Table 2a-c). Two out of three A1ATD-hIPSC primary lines differed from the fibroblasts from which they were derived, showing single-copy amplifications or deletions ranging from 20 kb to 1.3 Mb, including a gain of 20q11.21, a frequently amplified region in hESCs[21,22] (see Supplementary Analysis and Supplementary Fig. 4 for more detail). Line A retained a normal genome content compared to its parental fibroblast. Reassuringly, we found that after ZFN-stimulated targeting, four out of six homozygous clones had unaltered genomes compared to their parental hIPSC lines. Sixteen cell lines with bi-allelic *piggyBac* excision were compared with their corresponding primary hIPSCs and 12 had unaltered genomes. We also analyzed the hIPSC lines by high-density SNP arrays to check for loss of heterozygosity and found that all lines analyzed retained heterozygosity throughout their genome (Supplementary Fig. 5). This observation demonstrates that bi-allelic gene correction was the result of simultaneous homologous recombination followed by simultaneous excision at both alleles and that mitotic recombination was not involved in this process.

To further confirm that ZFN-stimulated targeting or *piggyBac* excision were not mutagenic at a single basepair resolution, we sequenced the exomes of the corrected B-16-C2 line and the original parental fibroblast. Comparison of these exomes identified 29 mutations. The genesis of these mutations was determined by analysis of the primary hIPSC line and the bi-allelic targeted intermediate before *piggyBac* excision. Twenty-four point mutations and one 1-bp deletion were detected in the primary hIPSC line and four mutations arose during genetic correction: one during targeting and three during

piggyBac excision. These mutations appeared to arise during culture since their genomic signatures were inconsistent with ZFN off-target sites or *piggyBac* integration sites (Supplementary Analysis). Taken together, we conclude that the combination of ZFNs with *piggyBac* provides a new method for rapid and clean correction of a point mutation in hIPSCs without affecting their basic characteristics.

To confirm that the genetic correction of hIPSCs resulted in the expected phenotypic correction, hIPSCs were differentiated *in vitro* into hepatocytes, the main cell type affected by the disease A1ATD. Differentiation of the corrected lines occurred as expected; by day 3 approximately 80% of cells expressed the endoderm marker CXCR4 and at the end of the protocol 80% of the cells expressed albumin (Supplementary Fig. 6a-c), confirming that c-hIPSCs can differentiate into a near homogenous population of hepatocytes. Remarkably, CGH analysis using differentiated hepatocytes showed that hepatic differentiation neither increases the number of genetic abnormalities nor selects for cells with abnormal karyotype (Supplementary Table 2d). Furthermore, the resulting cells shared key functional attributes of their *in vivo* counterparts including glycogen storage, LDL Cholesterol incorporation, albumin secretion and Cytochrome P450 drug metabolism (Supplementary Fig. 6d-g). Importantly, immunofluorescence and ELISA both confirmed the absence of mutant polymeric A1AT in c-hIPSCs-derived hepatocytes (Fig. 3a-c) that instead efficiently secreted normal endoglycosidase–H-insensitive monomeric A1AT (Fig. 3d). In addition, secreted A1AT displayed an enzymatic inhibitory activity that was comparable to that obtained from normal adult hepatocytes (Fig. 3e), thereby suggesting that physiological restoration of enzyme inhibitory activity could be achieved by use of such cells.

Finally, the *in vivo* function of corrected hIPSCs (B-C16-2 line) was assessed following transplantation into the liver of *Alb-uPA*$^{+/+}$*;Rag2*$^{-/-}$*;Il2rg*$^{-/-}$ mice via intra-splenic injection. Livers harvested 14 days after injection were colonized by human cells identified using antibodies specific to human albumin and A1AT (Fig. 3f, g). These human hepatocytes were distributed throughout the liver lobes and were seen to be integrated into the existing mouse parenchyma (Fig. 3f, g). In addition, human albumin was

detected in the serum of transplanted animals for at least 5 weeks (Fig. 3h), while no tumor formation was detected in any mice. Therefore, c-hIPSCs-derived hepatocytes were able to colonize the liver *in vivo* and display functional activities characteristic of their human ESC-derived counterparts[23]. Collectively these analyses demonstrate that gene editing by ZFNs together with *piggyBac* had not impaired the capacity of hIPSCs to differentiate and that genetic correction of the *Z* mutation resulted in functional restoration of A1AT in patient-derived cells.

All experimental evidence above strongly support the applicability of genetic correction in patient-specific iPSCs for cell-based therapy of A1ATD. We therefore repeated the genetic correction in more clinically relevant cells using patient-specific iPSCs reprogrammed from fibroblasts with Sendaiviral vectors, an integration-free method (Supplementary Fig. 7a-f). One primary iPSC line with an intact genome by CGH analysis (Supplementary Fig. 7e and Supplementary Table 4) was corrected by the method described above. The final product, iPSC-3-G5-A7, had the corrected *A1AT*, had an intact genome compared to the parental fibroblast, and expressed normal A1AT protein when differentiated to hepatocytes (Supplementary Fig. 8 and Supplementary Table 4). This is the first demonstration of the generation of mutation-corrected patient-specific iPSCs, which could realize the therapeutic promise of hIPSCs.

In the present study, we demonstrate that ZFNs and *piggyBac* transposon enable simultaneous bi-allelic correction of diseased hIPSCs. No residual ectopic sequences remain at the site of correction and the genome appears to be undisturbed elsewhere. Although we could readily obtain cell lines without large genomic alterations during genetic modification, the resulting corrected hIPSCs carry 29 mutations in protein coding exons, of which 22 were non-synonymous or splice site mutations. The likely impact of this mutation load needs to be considered in the context of their likely functional impact, taking into account the normal germ-line load, accumulated somatic variation, the presence of compensating normal gene copies and the requirement for the gene product in the derived differentiated cells. From this point of view, only eight mutations might

affect gene functions in hepatocytes (Supplementary Table 3). Nevertheless, the corrected iPSCs could efficiently differentiate to hepatocytes and engraft into the animal model for liver injury without tumor formation. Therefore, limited genomic abnormalities might have restricted biological consequences. Careful screening of primary and corrected hiPSCs using deep sequencing analyses would contribute to the safe use of hIPSCs in clinical applications.

Finally, hIPSCs derived from different patients were effectively corrected, demonstrating that this method could be applied to a large number of A1ATD-hIPSC lines. Since the bi-allelic correction could be carried out in less than 4 months, our approach may be compatible with large-scale production of corrected patient-specific hIPSCs not only for A1ATD but also for other monogenic disorders.

Method summary

A1ATD-hIPSCs were described previously[15]. 2 x 10^6 hIPSCs were co-transfected with 5 μg of each ZFN expression vector and 2 μg of the donor template and selected in puromycin (1 μg/ml) 4 days after transfection. For transposon excision, homozygously targeted cells were transfected with 10 μg of pCMV-hyPBase[8], cultured for 4 days, replated and selected in 250 nM 1-(2-Deoxy-2-fluoro-beta-D-arabinofuranosyl)-5-indouracil (FIAU). To increase clonogenicity, cells were treated with ROCK inhibitor[24], Y-27632 (10 μM) 4 hours prior to dissociation and 24 hours post plating. Resulting colonies were picked 2 weeks later, analyzed by PCR and further verified by Southern blot analysis.

References

1 Takahashi, K. *et al.* Induction of pluripotent stem cells from adult human fibroblasts by defined factors. *Cell* **131**, 861-872 (2007)

2 Yu, J. *et al.* Induced pluripotent stem cell lines derived from human somatic cells. *Science* **318**, 1917-1920 (2007)

3 Stadtfeld, M. & Hochedlinger, K. Induced pluripotency: history, mechanisms, and applications. *Genes Dev* **24**, 2239-2263 (2010)

4 Hanna, J. *et al.* Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. *Science* **318**, 1920-1923 (2007)

5 Fairchild, P. J. The challenge of immunogenicity in the quest for induced pluripotency. *Nat Rev Immunol* **10**, 868-875 (2010)

6 Tenzen, T., Zembowicz, F. & Cowan, C. A. Genome modification in human embryonic stem cells. *J Cell Physiol* **222**, 278-281 (2010)

7 Urnov, F. D., Rebar, E. J., Holmes, M. C., Zhang, H. S. & Gregory, P. D. Genome editing with engineered zinc finger nucleases. *Nat Rev Genet* **11**, 636-646 (2010)

8 Yusa, K., Zhou, L., Li, M. A., Bradley, A. & Craig, N. L. A hyperactive piggyBac transposase for mammalian applications. *Proc Natl Acad Sci U S A* **108**, 1531-1536 (2011)

9 Wang, W. *et al.* Chromosomal transposition of PiggyBac in mouse embryonic stem cells. *Proc Natl Acad Sci U S A* **105**, 9290-9295 (2008)

10 Hockemeyer, D. *et al.* Efficient targeting of expressed and silent genes in human ESCs and iPSCs using zinc-finger nucleases. *Nat Biotechnol* **27**, 851-857 (2009)

11 van der Weyden, L., Adams, D. J. & Bradley, A. Tools for targeted manipulation of the mouse genome. *Physiol Genomics* **11**, 133-164 (2002)

12 Lacoste, A., Berenshteyn, F. & Brivanlou, A. H. An efficient and reversible transposable system for gene delivery and lineage-specific differentiation in human embryonic stem cells. *Cell Stem Cell* **5**, 332-342 (2009)

13 Fraser, M. J., Ciszczon, T., Elick, T. & Bauser, C. Precise excision of TTAA-specific

lepidopteran transposons piggyBac (IFP2) and tagalong (TFP3) from the baculovirus genome in cell lines from two species of Lepidoptera. *Insect Mol Biol* **5**, 141-151 (1996)

14 Yusa, K., Rad, R., Takeda, J. & Bradley, A. Generation of transgene-free induced pluripotent mouse stem cells by the piggyBac transposon. *Nat Methods* **6**, 363-369 (2009)

15 Rashid, S. T. *et al.* Modeling inherited metabolic disorders of the liver using human induced pluripotent stem cells. *J Clin Invest* **120**, 3127-3136 (2010)

16 Perlmutter, D. H. Autophagic disposal of the aggregation-prone protein that causes liver inflammation and carcinogenesis in alpha-1-antitrypsin deficiency. *Cell Death Differ* **16**, 39-45 (2009).

17 Gooptu, B. & Lomas, D. A. Conformational pathology of the serpins: themes, variations, and therapeutic strategies. *Annu Rev Biochem* **78**, 147-176 (2009)

18 Zou, J. *et al.* Gene targeting of a disease-related gene in human induced pluripotent stem and embryonic stem cells. *Cell Stem Cell* **5**, 97-110 (2009)

19 Mitalipova, M. M. *et al.* Preserving the genetic integrity of human embryonic stem cells. *Nat Biotechnol* **23**, 19-20 (2005)

20 Baker, D. E. *et al.* Adaptation to culture of human embryonic stem cells and oncogenesis in vivo. *Nat Biotechnol* **25**, 207-215 (2007)

21 Lefort, N. *et al.* Human embryonic stem cells reveal recurrent genomic instability at 20q11.21. *Nat Biotechnol* **26**, 1364-1366 (2008)

22 Spits, C. *et al.* Recurrent chromosomal abnormalities in human embryonic stem cells. *Nat Biotechnol* **26**, 1361-1363 (2008)

23 Touboul, T. *et al.* Generation of functional hepatocytes from human embryonic stem cells under chemically defined conditions that recapitulate liver development. *Hepatology* **51**, 1754-1765 (2010)

24 Watanabe, K. *et al.* A ROCK inhibitor permits survival of dissociated human embryonic stem cells. *Nat Biotechnol* **25**, 681-686 (2007)

Acknowledgements

We thank Sir Aaron Klug and Dr Michal Minczuk for their advice, M.A. Li for comments on the manuscript, P. Ellis, N. Hammond and C. McGee for CGH analysis, the Sanger Institute sequencing facility for exome sequencing, N. Conte and S. Rice for assistance with bioinformatic analysis, M. Alexander for her help with cell culture reagents. We also thank S. Hinkley and the production group for ZFN assembly and validation, K. Tong and X. Meng for technical assistance, J.C. Miller and E. Leung for ZFN off-target site analysis and S. Abrahamson and P.D. Gregory for careful reading of the manuscript. This work was supported by Wellcome Trust (WT077187; A.B.), MRC Senior non-clinical fellowship and the Cambridge Hospitals National Institute for Health Research Biomedical Research Center (L.V.), the Medical Research Council and Papworth NHS Trust (D.A.L), Bill and Melinda Gates Foundation, Inserm and Institut Pasteur (H.S). K.Y. is supported by postdoctoral fellowship of Japan Society for the Promotion of Science. S.T.R and F.R. are Wellcome Trust Clinical Training Fellows. I.V. is supported by a fellowship from the International Human Frotiers Science Program Organization.

Author Contributions

K.Y. and S.T.R. are joint first authors. D.A.L., A.B. and L.V. contributed equally to this work. K.Y., S.T.R. D.A.L. A.B. and L.V. conceived of the research and wrote the manuscript with comments from all authors. K.Y. performed gene correction in mouse and human IPSCs and conducted all experiments using *piggyBac* in Cambridge, UK. S.T.R., E.M., A.O., N.H., F.R., G.A. and S.J.M. performed *in vitro* phenotypic analysis of corrected hIPSCs. S.T.R., H.S.M., S.D. and J.S. performed *in vivo* work. I.V. performed data analysis of exome sequencing. N.F. generated Sendaivirus vectors. P.L., D.E.P. and M.C.H. generated ZFNs.

Author Information

P-Q.L., D.E.P. and M.C.H. are employees of Sangamo BioSciences. N.F. is an employee of DNAVEC. All other authors declare no competing financial interests.

Table 1. Summary of gene correction experiments

a Summary of PCR genotyping of ZFN-stimulated gene targeting

A1ATD-iPSC line	Clones analyzed	Het.[a]	Homo. / Hemi. [b]	Het. + additional integrations [c]	Homo. / Hemi. + additional integrations [c]	Non-targeted [d]
A	84	45	3	23	8	5
B	18	10	2	3	3	0
C [e]	216	112	9	52	21	22
Mean frequency [%]		54	6	23	12	5

b Summary of frequencies of bi-allelic *piggyBac* excision

		Bi-allelic excision w/o re-integration		Bi-allelic excision w/ re-integration	
Cell line	Clones analyzed	No. of clones	Frequency [%]	No. of clones	Frequency [%]
B-16	88	15	17	33	38
C-G4	94	5	5	19	20
		Mean frequency [%]	11		29

[a] Het., clones heterozygous for *PB* allele. [b] Homo./Hemi., clones homozygous or hemizygous for *PB* allele. Cells with one targeted allele and deletion of the other allele are undistinguishable from correctly targeted homozygous clones by PCR. Such cells are designated as hemizygotes. [c] Vector backbone integration was analyzed by PCR. [d] Clones showing incorrect PCR bands are included. [e] A sum of 2 independent experiments.

Figure Legends

Figure 1. Correction of the G290T mutation in the *Tyr* gene in mIPSCs.

a, The strategy for precise genome modification using the *piggyBac* transposon. Top line, structure of the *Tyr* gene; red line, 5' external probe for Southern blot analysis; open arrow, *piggyBac* transposon carrying a *PGK-puΔtk* cassette; P1, P2 and P3, primers for PCR; B, *Bam*HI; E, *Eco*NI. **b**, **c**, Southern blot (**b**) and PCR analyses (**c**) showing insertion (c/PB) and excision (c/Rev) of the *piggyBac* transposon in the *Tyr* gene. mESCs (ES) were used as a positive control. **d**, **e**, Sequence analyses revealed correction of the G290T mutation (**d**) and seamless excision of the *piggyBac* transposon (**e**). Note that two silent mutations (A and T indicated by black arrowheads) introduced near the TTAA site by homologous recombination were also detected. **f**, A chimeric mouse generated by injecting corrected $Tyr^{c/Rev}$ mIPSCs (left) displays black coat color, confirming phenotypic correction of the albino mutation. Non-injected albino blastocyst was used as a control (right).

Figure 2. Correction of the *Z* mutation in A1ATD-hIPSCs.

a, The strategy for precise genome modification using ZFNs and the *piggyBac* transposon. Top line, structure of the *A1AT* gene; blue lines, Southern blot probes; open thin and thick boxes, non-cording and cording exons, respectively; open arrow, *piggyBac* transposon; B, *Bam*HI; A, *Afl*III. **b**, Sequences of wild-type allele (Reference), *Z* allele responsible for A1ATD, and *PB* allele carrying the *piggyBac* transposon. Amino acid position 342 (blue), recognition sites for ZFNs (green), *piggyBac* excision site (red) are shown. Sequence changes in *Rev* allele from *Z* allele were indicated by asterisks. **c**, Surveyor nuclease assay showing the cleavage of Z mutation in ZFNs-transfected K562 cells. Non-transfected cells were used as a control. **d**, Southern blot analysis showing bi-allelic *piggyBac* insertion (B-16) and bi-allelic excision (B-16-C2, B-16-C3 and B-16-C6) during correction of the A1ATD-hIPSCs line B. Genomic DNA was digested by *Bam*HI (5' and PB probes) or *Alf*III (3' probe). Genotype are described as follow: ZZ, homozygous

for *Z* allele; PP, homozygous for insertion of *piggyBac*; RR, homozygous for reverted allele. **e**, Sequence analysis showing correction of *Z* mutation in 3 corrected hIPSC lines. Wild-type sequence (top line) and A1ATD-hIPSC (second line). Z point mutation (A) was corrected to wild-type sequence (G) while precise *piggyBac* excision generated a TTAA site, which does not change amino acid sequence.

Figure 3. Functional analysis of restored A1AT in c-hIPSCs-derived hepatocytes.

a, Immunofluorescence showing the absence of polymeric A1AT protein in hepatocytes generated from c-hIPSCs. All forms of A1AT (left panels) and misfolded polymeric A1AT (middle panels). **b**, **c**, ELISA to assess the intracellular (**b**) and secreted (**c**) levels of polymeric A1AT protein in hepatocytes derived from A1ATD-hIPSCs (ZZ), c-hIPSCs (RR) and control hIPSCs (++). **d**, Endoglycosidase H (E) and peptide:*N*-glycosidase (P) digestion of A1AT immunoprecipitated from uncorrected (ZZ), corrected (RR) and control (++) hIPSC-derived hepatocytes (upper panels) and corresponding culture medium (lower panels), confirming the absence of A1AT intra-cellular accumulation in corrected hIPSCs. **e**, Chymotrypsin ELISA showing that corrected cells (RR) have A1AT enzymatic inhibitory activity that is superior to uncorrected cells (ZZ) and close to adult hepatocytes. **f**, ELISA read-out of human albumin in the mouse serum longitudinally followed for each mouse. Asterisk, the mouse was subjected to histology analysis. **g**, **h**, Immunofluorescence of transplanted liver sections detecting human albumin (**g**) and A1AT (**h**). DNA was counterstained with DAPI.

Scale bars, 100 μm. Data in **b**, **c** and **e** are shown as mean ± s.d. (*n*=3). Student's *t*-test was performed. NS, not significant.

Methods

Plasmid construction

Gateway-adapted *piggyBac* transposon vectors: A destination vector pPB-R1R2-NP was constructed as follows. The *att*R1 and *att*R2 sites were PCR-generated and digested by *Nhe*I/*Hin*dIII and *Xho*I/*Spe*I, respectively. *EM7-neo* was PCR-generated and digested by *Hin*dIII/*Xho*I. These 3 fragments were then cloned into the *Nhe*I-*Spe*I site of pPB-LR5 [25], resulting in pPB-R1R2-Neo. An *Eco*RI-*Xba*I fragment containing *PheS* was excised from pR6K-R1R2-ZP[26], blunt-ended and cloned into the blunted *Xho*I site of pPB-R1R2-Neo, resulting in pPB-R1R2-NP. An entry vector pENTR-*PGKpuΔtk* was constructed by cloning a *Kpn*I-*Not*I *PGK-puΔtk* fragment into the *Kpn*I-*Not*I site of pENTR-2B.

A targeting vector for *Tyr*: The targeting vector was constructed using BAC recombineering. A BAC clone RP24-221M7 was introduced into *Escherichia coli* strain EL350 [27]. A mini targeting vector was first constructed to modify the *Tyr* gene on the BAC. Left and right homology arms were PCR-generated and digested by *Asc*I/*Bsi*WI and *Nsi*I/*Pac*I, respectively. The transposon fragment was excised from pPB-R1R2-NP by *Nsi*I/*Bsi*WI digestion. These 3 fragments were then cloned into *Asc*I/*Pac*I site of pMCS, resulting in pMCS-Tyr-NP. An *Asc*I-*Pac*I fragment was excised from pMSC-Tyr-NP and used for BAC targeting. A retrieving vector was constructed by cloning PCR-generated left and right homology arm into the *Xho*I/*Asc*I site of pMSC-DTA, following *Asc*I/*Hin*dIII and *Xho*I/*Hin*dIII digestion of the left and right arm, respectively. The retrieving vector was linearized by *Hin*dIII digestion and used to retrieve 3.0-kb 5′ arm, the transposon and 6.5-kb 3′ arm. Finally, the *Neo-PheS* cassette was replaced with the *PGK-puΔtk* cassette by Gateway cloning, resulting in pDTA-Tyr^{PB}. The targeting vector was linearized by *Asc*I prior to electroporation into the albino mIPSCs.

A donor template vector for *A1AT*: A 2-kb fragment, which contained 1 kb at both side of Z mutation, was first PCR-amplified using genomic DNA from A1ATD-hIPSC line B as a

template and cloned into pCR4-blunt-TOPO (Invitrogen), resulting in pCR4-AAT_Z. To construct a donor template with corrected sequence and a *piggyBac* transposon, the 5′ arm and 3′ arm were PCR-amplified and digested with *Asc*I/*Nsi*I and *Bsi*WI/*Pac*I, respectively. The *Nsi*I-*Bsi*WI fragment containing a *piggyBac* transposon with the *Neo-PheS* cassette was excised from pPB-R1R2-NP. The digested fragments were cloned into the *Asc*I-*Pac*I site of pMCS, resulting in pMCS-AAT-PB:NP. The *Neo-PheS* cassette was subsequently replaced with a *PGK-puΔtk* cassette by Gateway cloning, resulting in the final donor vector, pMCS-AAT-PB:*PGKpuΔtk*.

The plasmids (pPB-R1R2-NP, pENTR-*PGKpuΔtk*, pMCS-AAT-PB:*PGKpuΔtk*) are deposited in the Wellcome Trust Sanger Institute Archives and available upon request (http://www.sanger.ac.uk/technology/clonerequests/).

Cell culture

Mouse embryonic fibroblasts (CF1 or B6129F1) were cultured in DMEM containing 10 % FCS, 2 mM Glutamine, 0.1 mM 2-melcaptoethanol and 1x non-essential amino acid. mIPSCs (iPS25Δ1; ref. [14]) were cultured on MEF-feeder layers in mESC medium: KO-DMEM supplemented with 15 % FBS, 1 mM GlutaMax, 0.1 mM 2-mercaptoethanol, 1x non-essential amino acid and 1000 U/ml LIF (Millipore). A1ATD-hIPSCs (ref. [15]; A, patient 2 line 1; B, patient 1 line1; C, patient 3 line1) were cultured on MEF-feeder layers in hESC medium: DMEM/F12 supplemented with 20 % knockout serum replacement, 1 mM GlutaMax, 0.1 mM 2-mercaptoethanol, 1x non-essential amino acid and 4 ng/ml FGF2 (Invitrogen). Subculture was performed every 5-7 days by detaching hIPSCs by incubation in 0.5 mg/ml dispase and 0.5 mg/ml collagenase type IV for 1 hr at 37 °C, collecting detached hIPSC colonies, breaking down into small clamps and plating them onto new feeder plates.

Gene Targeting and transposon excision in mouse IPSCs

1 x 10^7 cells were electroporated with 25 μg of a linearized targeting vector in 800 μl of HEPES-buffered saline using a Gene Pulser II electroporator (230 V, 500 μF) and plated

onto one-to-three 10-cm dish. The next day, puromycin selection (1 μg/ml) was initiated. Resulting colonies were picked and screened by PCR. Targeted clones were expanded and further verified by Southern blot analysis. Correctly targeted clones were then subjected to transposon excision. 2 x 10^6 cells were electroporated with 40 μg of pCMV-hyPBase in 800 μl of HEPES-buffered saline using a Gene Pulser II electroporator (230 V, 500 μF) and plated onto one well of a 6-well plate. After passage once, cells were replated on day 4 at 5 x 10^5 cells per 10-cm dish. On the following day, FIAU (0.2 μM) selection was initiated. On day 5 of selection, FIAU was withdrawn. Resulting colonies were picked at day 7 and screened by PCR. Primer sequences to detect homologous recombination are shown in Supplementary Table 2.

ZFNs-mediated gene targeting in A1ATD-hIPSCs.

On the day of electropolation (day 0), near-confluent cells were pre-treated with a ROCK inhibitor [24] (Y-27632, Sigma) at 10 μM for 3-4 hrs prior to electroporation. Cells were then washed with PBS once, detached by Accutase (Millipore; 10 min at 37 °C) and mixed with DMEM/F12 containing 10% FCS. Cells were dissociated into single-cell suspension by vigorous pipetting and counted. 2 x 10^6 cells were pelleted and mixed with 5 μg of a 5′-ZFN expression vector, 5 μg of a 3′-ZFN expression vector and 2 μg of the donor template in 100 μl of hESC solution 1 (Lonza). The cell suspension was transferred to a cuvette and electroporated using the Amaxa Nucleofector device (Lonza) with program A23. The electroporated cells were plated onto one or two 10-cm feeder dish in MEF-conditioned hESC medium containing 10 μM Y-27632. hESC medium without any drug was used for daily medium change between day 1-3. On day 4, puromycin selection (1 μg/ml) was started. On day 6, medium was changed to MEF-conditioned hESC medium containing 0.5 μg/ml puromycin, which was used for medium change at every other day until picking colonies. Resulting colonies were picked on day 13-17. Colonies was cut into 2 pieces. One half was transferred onto a well of 24-well feeder plate and the other half was lysed and used for PCR-genotyping. PCR-positive clones were further expanded and homologous recombination was verified by Southern blot

analysis.

Transposon excision in homozygously targeted hIPSCs.

Cells were prepared as described above. 2 x 10^6 cells were mixed with 10 μg of the hyperactive piggyBac transposase expression vector (pCMV-hyPBase [8]) in 100 μl of hESC solution 1 and electroporated using the Nucleofector device with the program A23. Electroporated cells were plated onto 6-well plate in 1:2, 1:3 and 1:6 dilutions in MEF-conditioned hESC medium containing 10 μM Y-27632. Note that ROCK inhibitor was added to the culture medium until day 6 in this experiment. On day 2, cells with ~80 % confluency were passaged using Accuate at a split ratio 1:2, 1:3 and 1:6 into 6-well plates. On day 4, cells with ~80 % confluency were washed with PBS, detached with Accutase, suspended in hESC medium and pelleted. Cells were resuspended in hESC medium into single-cell level and counted. 1 x 10^4 cells were then plated onto one 10-cm dish in hESC medium containing 10 μM Y-27632. 16-18 hrs after plating (day 5), medium was changed to hESC medium containing 0.25 μM FIAU and 10 μM Y-27632. On day 6, medium was changed to hESC medium containing 0.25 μM FIAU and then medium was changed every other day. Genotype and deletion of the *piggyBac* transposon were analyzed by PCR and further verified by Southern blot analysis.

CGH analysis

Genomic DNA was extracted using a DNeasy kit (Qiagen). Agilent 244K human genome arrays were used following the manufacturer's protocol. The arrays were scanned with an Agilent microarray scanner and data were generated by Agilent Feature Extraction software. CGH calls were made with Agilent's DNA analytics software using the ADM2 algorithm (6.0 threshold) with a minimum of 5 probes in the region as a filter.

SNP analysis

An Illumina HumanCytoSNP-12 SNP array was used following the manufacturer's protocol. Genotype calls were performed by Illumina's GenomeStudio. B allele frequency

and log R ratio were analyzed by KaryoStudio. CNVpatition v2.4.4 bundled in KaryoStudio was used for copy number analysis.

ZFN design

ZFNs were designed against a region containing *Z* mutation in the *A1AT* gene (see Fig. 2a, b) and assembled as previously described[28]. The amino acid residues at positions '-1' to '+6' of the recognition alpha helix[29,30] of each of the zinc finger DNA-binding domain for each DNA triplet target are shown in Supplementary Table 2. The ZFNs were linked to wild type *Fok*I catalytic domain. The activity of the ZFN at the endogenous target site was determined using the Surveyor Nuclease assay as previously described[31].

hIPSCs-derived hepatocyte transplantation in immunodeficient uPA transgenic mice

Animal studies were conducted under protocols approved by the French Ministry of Agriculture. Differentiated cells (5×10^5 cells per animal in 50 µl DMEM) were injected into the spleens of 3- to 4-week-old *Alb-uPA*$^{+/+}$;*Rag2*$^{-/-}$;*Il2rg*$^{-/-}$ mice (*n*=7). The recipient mouse was sacrificed 2 weeks after transplantation for histological analysis. Blood samples were collected and human albumin in plasma was quantified by ELISA (Bethy Laboratories). Frozen liver sections were analyzed by immunofluorecence with human albumin (Dako) or human A1AT (Dako) specific antibodies. Non-transplanted mice were used as controls.

Exome sequencing

The corrected iPSC line, B-16-C2, and its parental fibroblasts were analyzed. Exome sequencing and analysis were performed as described previously[32] with minor modification. Exome pulldown was performed using an Agilent SureSelect Human All Exon 50Mb Kit according to the manufacturer's instructions. Enriched DNA was sequenced on Illumina HiSeq2000. 90.32% (Fibroblast-B) and 90.72% (B-16-C2) of total targeted regions were covered with more than 10x sequencing depth, covering 93.01%

and 93.35% of CCDS exons, respectively. Substitutions in the coding sequence were called as positions with at least 20% of reads reporting a different base with respect the reference human sequence (GRCh37). Additionally, somatic mutations were identified by comparing the sequence with the control fibroblasts, and removing the common polymorphisms described in dbSNP and in the 1000 Genomes Project[33]. Small insertions and deletions were identified using samtools, as the ones not present in the control cell line and that had at least 20x of coverage and 20% of the reads reporting the mutation. Validation of mutations was carried out by Sanger capillary sequencing on parental Fibroblast-B, A1ATD-hiPSC line B, the homozygously targeted B-16 cells and the *piggyBac*-excised B-16-C2 cells.

Sendaiviral regrogramming, RT-PCR, quantitative RT-PCR, bisulfite sequencing, immunostaining, flow cytometric analysis, ELISA and EndoH analysis

These experiments were performed as described previously [15,23,34]

25 Cadinanos, J. & Bradley, A. Generation of an inducible and optimized piggyBac transposon system. *Nucleic Acids Res* **35**, e87 (2007).

26 Skarnes, W. C. *et al.* A conditional knockout resource for the genome-wide study of mouse gene function. *Nature* **474**, 337-342 (2011).

27 Liu, P., Jenkins, N. A. & Copeland, N. G. A highly efficient recombineering-based method for generating conditional knockout mutations. *Genome Res* **13**, 476-48 (2003).

28 Urnov, F. D. *et al.* Highly efficient endogenous human gene correction using designed zinc-finger nucleases. *Nature* **435**, 646-651 (2005).

29 Beerli, R. R. & Barbas, C. F., 3rd. Engineering polydactyl zinc-finger transcription factors. *Nat Biotechnol* **20**, 135-141 (2002).

30 Pavletich, N. P. & Pabo, C. O. Zinc finger-DNA recognition: crystal structure of a Zif268-DNA complex at 2.1 A. *Science* **252**, 809-817 (1991).

31 Guschin, D. Y. *et al.* A rapid and general assay for monitoring endogenous gene

modification. *Methods Mol Biol* **649**, 247-256 (2010).

32 Varela, I. *et al.* Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. *Nature* **469**, 539-542 (2011).

33 Consortium, T. G. P. A map of human genome variation from population-scale sequencing. *Nature* **467**, 1061-1073 (2010)

34 Seki, T. *et al.* Generation of induced pluripotent stem cells from human terminally differentiated circulating T cells. *Cell Stem Cell* **7**, 11-14 (2010)